Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Unknown 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 4Gastrointestinal 4Thoracic 3Gynecologic 2Genitourinary 2Dermatologic 2Other solid neoplasm 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 50Lung Neoplasms 13Neoplasms 8Melanoma 6Neoplasm Metastasis 5Head and Neck Neoplasms 5Squamous Cell Carcinoma of Head and Neck 4Breast Neoplasms 4Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Ovarian Neoplasms 3Colorectal Neoplasms 3Carcinoma, Merkel Cell 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Mesothelioma, Malignant 2Gastrointestinal Neoplasms 2Colonic Neoplasms 2Carcinoma, Squamous Cell 2Carcinoma, Renal Cell 2Carcinoma, Large Cell 2Carcinoma, Basal Cell 2Brain Neoplasms 2Advanced Non-Small Cell Lung Cancer 2Adenocarcinoma 2Vaccinia 1Uterine Neoplasms 1

Interventions

pembrolizumab 24Nivolumab 19atezolizumab 9Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7durvalumab 5Ipilimumab 5fludarabine 4Trastuzumab 4cemiplimab 3cabozantinib 3avelumab 3Sunitinib 3Biopsy 3ulixertinib 2toripalimab 2tislelizumab 2spartalizumab 2sargramostim 2relatlimab 2palbociclib 2lenvatinib 2epacadostat 2enzalutamide 2cyclopropapyrroloindole 2copanlisib 2budigalimab 2aldesleukin 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × cemiplimab × Thoracic × Clear all
NCT03916627 2026-04-06

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Regeneron Pharmaceuticals

Phase 2 Active not recruiting
65 enrolled
GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular

NCT06923761 2026-01-28

EMITT-1

Grey Wolf Therapeutics

Phase 1/2 Recruiting
300 enrolled
GastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Lung Neoplasms, Neoplasms

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Jules Bordet Institute

Phase 2 Unknown
441 enrolled
BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡